Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Lexeo Therapeutics Inc (LXEO)

Lexeo Therapeutics Inc (LXEO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights GlobeNewswire - Mon Mar 30, 3:05PM CDT

SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026 First CMC Development and Readiness...

LXEO : 6.53 (-5.50%)
LXEO's Cardiac Gene Therapy Data Finally Arrives: The Pivot Wall Street Demanded or Another Clinical Stall? Barchart - Sun Mar 29, 4:00PM CDT

Barchart Research What to Expect from LXEO Earnings LXEO Generated March 28, 2026 Current Price $5.46 EPS Estimate $-0.32 Consensus Rating Strong Buy Average Move 8.90% LXEO's Cardiac Gene Therapy Data...

LXEO : 6.53 (-5.50%)
LXEO's Cardiac Gene Therapy Data Finally Arrives: The Pivot Wall Street Demanded or Another Clinical Stall? Barchart - Sat Mar 28, 4:01PM CDT

Barchart Research What to Expect from LXEO Earnings LXEO Generated March 28, 2026 Current Price $5.46 EPS Estimate $-0.32 Consensus Rating Strong Buy Average Move 8.90% LXEO's Cardiac Gene Therapy Data...

LXEO : 6.53 (-5.50%)
Payroll Figures Due in Canada Next Week Baystreet - Mon Mar 23, 12:50AM CDT

Monday Economic Lookahead Construction spending (delayed report) (Jan.) Featured Earnings ...

CNM : 50.00 (-1.56%)
HUMA : 0.6875 (-3.20%)
CNTA : 39.51 (-0.38%)
AIR : 121.97 (-0.87%)
IMMX : 10.09 (-2.51%)
SA : 33.04 (-1.67%)
CDZI : 4.97 (+2.69%)
SFD : 28.56 (-1.52%)
AGX : 611.21 (+2.23%)
LXEO : 6.53 (-5.50%)
PAYX : 93.09 (+1.23%)
SBC : 3.72 (-17.15%)
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference GlobeNewswire - Tue Mar 3, 6:30AM CST

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases,...

LXEO : 6.53 (-5.50%)
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February GlobeNewswire - Thu Feb 5, 6:30AM CST

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases,...

LXEO : 6.53 (-5.50%)
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics GlobeNewswire - Tue Jan 27, 6:30AM CST

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases,...

LXEO : 6.53 (-5.50%)
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy GlobeNewswire - Mon Jan 12, 6:00AM CST

LX2020 generally well tolerated across ten participants with no clinically significant complement activation  LX2020 transduction, transcription, and increased protein expression observed across...

LXEO : 6.53 (-5.50%)
Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy GlobeNewswire - Thu Jan 8, 6:00AM CST

Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson’s expertise in cardiovascular therapeutics and circulatory technologies, including Impella™ heart pumps ...

LXEO : 6.53 (-5.50%)
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Mon Dec 22, 2025

NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc . (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases,...

LXEO : 6.53 (-5.50%)

Barchart Exclusives

As Costco Raises Its Dividend More Than 13%, Should You Buy, Sell, or Hold COST Stock? Barchart - 14 minutes ago
Costco raised its quarterly dividend 13.1% to $1.47 per share. Here's what investors need to know before deciding to buy, sell, or hold COST stock right now. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.